2 October 2026
Sidley Represents Jiangsu Hengrui in Connection With US$2.6 Billion Licensing Agreement With Novo Nordisk
Advising firms
Deal team
12 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Lila Hope Lead | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Jennifer Raab Lead | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Jiqiang Lin Lead | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Arif Noorani | Sidley | Not stated | Food, Drug and Medical Device | Not stated |
| Chen Yang | Sidley | Not stated | Food, Drug and Medical Device | Not stated |
| Elizabeth Hardcastle | Sidley | Not stated | Healthcare | Not stated |
| Taylor Andelman | Sidley | Not stated | Healthcare | Not stated |
| Michael Alcan | Sidley | Not stated | Tax | Not stated |
| Sophie Arkusinski | Sidley | Not stated | Tax | Not stated |
| Miriam Carroll Silvestri | Sidley | Not stated | Antitrust and Competition | Not stated |
| Ash Nagdev | Sidley | Not stated | Privacy and Cybersecurity | Not stated |
| Stephanie Lim | Sidley | Not stated | Privacy and Cybersecurity | Not stated |
9 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 2.60bn (US$2.6 billion)
- What the figure measures
- Total transaction value
- Client
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.Sell-side
- Counterparties
- Novo Nordisk (Buy-side)